I read with great interest the recently published manuscript in Endocrine from Hescot et al. [1] in which they report similar results to what we had already reported in 2018 [2].

In this investigation, the authors showed that after comparing those pathological reports which had a second-opinion diagnosis, these histopathological modifications led to changes in the ATA 2015 risk stratification classification in 31% of patients. In our investigation, after reviewing historical pathological reports, this situation happened in 25% of our cases which led to a better refining of the prediction of the initial structural or excellent response to treatment. We are happy that our idea was similarly replicated in Europe with very comparable results.